StockData
Akari Therapeutics Plc logo

Akari Therapeutics Plc (AKTX) stock

AKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 0/30
$5.70−0.81 (-12.44%)

Close on Nov 17, 2026Market cap $11.10MP/E –Yield –

Akari Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Akari Therapeutics's ebitda for the twelve months ending Dec 31, 2024 was -$21.63M. For fiscal 2024 it was -$21.63M. The highest annual figure on record is -$1.91M in fiscal 2014.

Annual ebitda

PeriodPeriod endValueChange
FY2024Dec 31, 2024-$21.63M–
FY2023Dec 31, 2023-$16.80M–
FY2022Dec 31, 2022-$23.08M–
FY2021Dec 31, 2021-$17.21M–
FY2020Dec 31, 2020-$17.97M–
FY2019Dec 31, 2019-$16.94M–
FY2018Dec 31, 2018-$20.75M–
FY2017Dec 31, 2017-$37.74M–
FY2016Dec 31, 2016-$27.21M–
FY2015Dec 31, 2015-$30.57M–
FY2014Dec 31, 2014-$1.91M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2024Dec 31, 2024-$5.28M–
Q3 FY2024Sep 30, 2024-$2.93M–
Q2 FY2024Jun 30, 2024-$7.45M–
Q1 FY2024Mar 31, 2024-$5.98M–
Q4 FY2023Dec 31, 2023-$5.09M–
Q3 FY2023Sep 30, 2023-$2.51M–
Q2 FY2023Jun 30, 2023-$4.61M–
Q1 FY2023Mar 31, 2023-$4.59M–
Q4 FY2020Dec 31, 2020-$6.89M–
Q3 FY2020Sep 30, 2020-$245.90K–
Q2 FY2020Jun 30, 2020-$5.91M–
Q1 FY2020Mar 31, 2020-$4.92M-28187.0%
Q4 FY2019Dec 31, 2019-$7.82M–
Q3 FY2019Sep 30, 2019-$3.11M–
Q2 FY2019Jun 30, 2019-$6.03M–
Q1 FY2019Mar 31, 2019$17.53K–

More Akari Therapeutics figures

See a number that looks wrong?